Wednesday, April 2, 2025 4/2/2025

Effect of SIRPalpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA matched related donor

Award Number: R03CA289563
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Effect of SIRPalpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA matched related donor - PROJECT SUMMARY/ABSTRACT Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for patients with hematologic malignancies. It is believed that alloreactivity upon HSCT is initiated by lymphoid cells that express rearranging receptors upon recognizing the alloantigens on the graft. Unlike lymphoid cells, cells from the innate immune system do not express rearranging receptors and are nonspecifically induced by “danger” molecules. However, recent studies demonstrated that the innate immune system could specifically distinguish the non-self graft and subsequently enhance the alloimmune response. Signal regulatory protein α (SIRPα) is a polymorphic immunoglobulin receptor that is exclusively expressed on the surface of innate cells. The interaction between SIRPα and its ubiquitously expressed ligand, CD47, suppresses the macrophage's phagocytic function. As shown in the murine transplant model, mismatches of SIRPα between donor and recipients can upregulate the allorecognition response. Our group recently investigated the role of SIRPα variant mismatch in recipients of allo-HSCT from a human leukocyte antigen (HLA)-matched related donors (MRD) for the treatment of different hematological malignancies. We found that for the first time, donor/recipient SIRPα mismatch is commonly detected and associated with a significantly increased risk of chronic graft-versus-host disease (cGVHD) and a lower rate of early relapse (Blood Advances 2021; Frontier in Immunology 2022). We proposed a large registry-based study to validate our results in allo-HSCT recipients with MRD, which is one of the most common donor sources in allo-HSCT. The study is approved by the Center for International Blood and Marrow Transplant Research (CIBMTR) immunobiology working committee. CIBMTR and the National Marrow Donor Program (NMDP) will facilitate the study by providing scientific and statistical expertise, as well as associated clinical outcome information and biospecimens. We hypothesize that the mismatched SIRPα elicits a non-self recognition which will further promote adaptive immunity leading to a higher risk of cGVHD and a lower risk of relapse. In Aim 1, we will perform a retrospective analysis of the SIRPα mismatch in allo-HSCT with MRD using the CIBMTR data and specimens. Aim 2 is to determine the relative clinical significance of SIRPα mismatch in the entire cohort and the subgroups of allo-HSCT. The study will not only define the clinical role of SIRPα variant mismatch in the allo-HSCT setting but also significantly advance our knowledge of GVHD/ Graft versus Leukemia (GVL) and the allorecognition of the innate immune system in the context of stem cell transplant.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $81,000 )
2025	2025	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	2	3/19/2025	NON-COMPETING CONTINUATION	$81,000
														Subtotal = $81,000

Issue Date FY: 2024 ( Subtotal = $81,000 )
2024	2024	THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	1	3/8/2024	NEW	$81,000
														Subtotal = $81,000

Grand Total All Awards = $162,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Effect of SIRPalpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA matched related donor

Award Number: R03CA289563

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer